Korean J Transplant.  2022 Nov;36(Supple 1):S250. 10.4285/ATW2022.F-3896.

QuantiFERON cytomegalovirus assay for evaluation of CMV reactivity among renal transplant recipient and donor in Bangladesh

• Nobi F
• Bari A
• Salma Begum NA
• Kashem TS
• Uz-Zaman Arefin MS
• Nomany S
• Rahman M
• Akhter N
• Yousuf E
• Rashid HU

• KMID: 2535467
• DOI: http://doi.org/10.4285/ATW2022.F-3896

Abstract

Background
CMV is the one of the most common viral infections after kidney transplantation with significant morbidity and mortality. Currently sero-positivity for CMV IgG before solid organ transplantation is the laboratory test of choice for stratifying the risk of CMV reactivation after transplantation. Test for CMV specific T cell responses have been proposed to change the current risk stratification strategy using CMV assays. We therefore tested QuantiFERON cytomegalovirus assay for evaluation of CMV reactivity among renal transplant recipient and donor in Bangladesh.
Methods
A retrospective study was done with 326 subjects from 2017 to 2021 in Kidney Foundation Hospital and Research Institute, Bangladesh. Data analyzed by statistical analysis software.
Results
In this study for assaying CMV reactivity by QuantiFERON cytomegalovirus assay, 326 subjects were included. The mean age was 38.5 (SD, 11.9) years, 140 (42.9%) were female, 186 (57.1%) were male. Among these 191 (58.6%) were recipients with mean age 34.3 (SD, 10.7) years and 135 (41.4%) were donors with mean age 44.4 (SD, 11.0) years. Among recipient 68 (20.86%) was reactive and 123 (37.7%) was non-reactive to QuantiFERON cytomegalovirus assay. Among donor 65 (19.94%) was reactive and 70 (21.47 %) was non-reactive to the assay. Recipients were significantly less reactive to donors (P<0.02). In our study younger people were less reactive to this assay (P<0.001) which can be explained by recipients being of younger age. In our study it has also been shown that most of the recipients being male 145 (76%) and donor being female 94 (70%).
Conclusions
This is the baseline study for evaluation of CMV reactivity in kidney recipients and donors of Bangladesh. This knowledge will be used for stratifying the risk of CMV reactivation after transplantation.